Neuromuscular Disorders
Volume 20, Issue 2 , Pages 148-151 , February 2010

The role of patient advocacy organisations in neuromuscular disease R&D – The case of the Dutch neuromuscular disease association VSN

  • Wouter Boon

      Affiliations

    • Department of Innovation and Environmental Studies, Utrecht University, Van Unnik 1013A, P.O. Box 80115, NL-3508 TC Utrecht, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 30 2537484/1625; fax: +31 30 2532746.
    • ,
  • Ria Broekgaarden

      Affiliations

    • Dutch Neuromuscular Disease Organisation VSN, Lt. gen. van Heutszlaan 6, NL-3743 JN Baarn, The Netherlands
    • Tel.: +31 35 5480480.

Received 9 October 2009 ,Revised 19 October 2009 ,Accepted 27 October 2009.

References 

  1. Van Weely S, Leufkens HGM. Priority medicines for Europe and the World a “Public health approach to innovation”. Orphan Diseases. Utrecht: WHO; 2004;pp. 7.5-1–7.5-35
  2. European Commission. Useful information on rare diseases from an EU perspective 2009. EU: Brussel; 2004.
  3. EPPOSI. Report of the 7th EPPOSI workshop on partnering for rare diseases therapy development: positioning rare diseases on the healthcare agenda. Madrid, Spain; 2006.
  4. WHO, Priority medicines for Europe and the World, World Health Organisation, Geneva; 2004, pp. 4–5.
  5. RGO, Advies Orphan Drugs (weesgeneesmiddelen). 1998, Raad voor Gezondheidsonderzoek: Den Haag.
  6. Boon WPC, Demanding dynamics – demand articulation of intermediary organisations in emerging pharmaceutical innovations (Ph.D. thesis). Utrecht: Utrecht University; 2008.
  7. VSN, VSN annual report 2005. Vereniging Spierziekten Nederland: Baarn; 2006.
  8. Epstein S. Activism, drug regulation, and the politics of therapeutic evaluation in the AIDS era: a case study of ddC and the ‘Surrogate Markers’ debate. Soc Stud Sci. 1997;27(5):691–726
  9. Rabeharisoa V. The struggle against neuromuscular diseases in France and the emergence of the “partnership model” of patient organisation. Soc Sci Med. 2003;57:2127–2136
  10. Epstein S. Patient groups and health movements. In:  Hackett EJ, et al. editor. Handbook of science and technology studies. 3rd ed.. Massachusetts: Cambridge; 2008;p. 499–537
  11. Emery AEH. The European Neuromuscular Centre (ENMC): importance of collaborative research. Neuromuscul Disord. 1997;7(2):135–137
  12. Rüdel R, Nigro G, Poortman Y. Ten years of ENMC – from a patients’ initiative to a successful European research institution: the story of the European Neuromuscular Centre. Neuromuscul Disord. 2000;10(1):75–82
  13. Schmid EF, Smith DA. Is pharmaceutical R&D just a game of chance or can strategy make a difference?. Drug Discov Today. 2004;9(1):18–26
  14. Vos R. Drugs looking for diseases. Groningen: Rijksuniversiteit Groningen; 1989;
  15. Von Hippel E. The sources of innovation. Oxford: University Press; 1988;
  16. Oudshoorn N, Pinch T. How users matter – the co-construction of users and technology. In:  Bijker W,  Carlson B,  Pinch T editor. Inside technology. Cambridge Machusetts: The MIT Press; 2003;
  17. Smits REHM, Boon WPC. The role of users in innovation in the pharmaceutical industry. Drug Discov Today. 2008;13(7/8):353–359
  18. Collins HM, Evans R. The third wave of science studies: studies of expertise and experience. Soc Stud Sci. 2002;32(2):235–296
  19. Caron-Flinterman JF, Broerse JEW, Bunders JFG. The experiential knowledge of patients: a new resource for biomedical research?. Soc Sci Med. 2005;60:2575–2584

PII: S0960-8966(09)00665-8

doi: 10.1016/j.nmd.2009.10.012

Neuromuscular Disorders
Volume 20, Issue 2 , Pages 148-151 , February 2010

Article Tools

* Image Usage & Resolution